Patent Regulatory and Institutional Mechanisms in Sub-Saharan Africa

Chapter

Abstract

The preceding chapters have informed us about the historical processes (and its inherent inequities) that led to the prevailing international patent system. The historically rooted marginalization of SSA countries and their citizens in the adoption and implementation of TRIPS pose a significant challenge to the functioning of the globalized patent regime and its domestic variations in SSA. In addition, the dominant economic rationale undergirding the globalized patent system promotes a one-size-fits-all system, which is a poor fit for the social conditions in SSA, and eventually contributes to impoverishing countries in SSA. These conclusions have been arrived at both by critiquing developments that led to TRIPS and by examining the theoretical justifications for patents. Today, those same power politics and the messianic assumptions that have served the economic interests of big pharma continue to shape the international patent system and its reflections in SSA.

Keywords

World Trade Organization Supra Note Patent Application Patent Office Compulsory License 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Bibliography

Literature

  1. ’t Hoen EFM (2009) The global politics of pharmaceutical monopoly power: drug patents, access, innovation and the application of WTO declaration on TRIPS and public health. AMB, AmsterdamGoogle Scholar
  2. Abbott FM (2005) Toward a new era of objective assessment in the field of TRIPS and variable geometry for the preservation of multilateralism. J Int Econ Law 8:77CrossRefGoogle Scholar
  3. Amani B (2009) State agency and the patenting of life in international law: merchants and missionaries in a global society. Ashgate, SurreyGoogle Scholar
  4. Avafia T et al (2010) Using competition law and policy to increase access to a sustainable supply of affordable medicines. In: Intellectual property and access to medicines: papers and perspectives. Geneva: WHO, pp 191. Online: http://203.90.70.117/PDS_DOCS/B4552.pdf
  5. Bedner AW (2008) Amalgamating environmental law in Indonesia. In: Arnscheidt J et al (eds) Lawmaking for development: explorations into the theory and practice of international legislative projects. Leiden University Press, LeidenGoogle Scholar
  6. Bhagwati J (2004) In defense of globalization. Oxford University Press, New YorkGoogle Scholar
  7. Boldrin M, Levine D (2008) Against intellectual monopoly. Cambridge University Press, New YorkGoogle Scholar
  8. Carrier MA (2004) Cabining intellectual property through a property paradigm. Duke Law J 54:1Google Scholar
  9. Correa C (2007) Guidelines for the examination of pharmaceutical patents: developing a public health perspective (Geneva, ICTSD, UNCTAD, WHO, UNDP, 2007). Online: http://www.emro.who.int/emp/media/pdf/patentability_guidelines.pdf
  10. Correa CM (2010) Intellectual property rights and public health: the general context and main trips compliant flexibilities. In: Intellectual property and access to medicines: papers and perspectives. Geneva: WHO, pp 11. Online: http://203.90.70.117/PDS_DOCS/B4552.pdf
  11. de Carvalho NP (2006) The TRIPS regime of trademarks and designs. Kluwer Law International, The HagueGoogle Scholar
  12. de Werra J (2009) Fighting against biopiracy: does the obligation to disclose in patent applications truly help? Vanderbilt J Transnatl Law 42:143Google Scholar
  13. Dreyfuss R et al (eds) (2004) Expanding the boundaries of intellectual property: innovation policy for the knowledge society. Oxford University Press, OxfordGoogle Scholar
  14. El-Said M (2005) The road from TRIPS-minus, to TRIPS, to TRIPS-plus: implications of IPRS for the Arab World. J World Intellect Prop 8:53CrossRefGoogle Scholar
  15. Endeshaw A (2002) The paradox of intellectual property law-making in the new millennium: universal templates as terms of surrender for non-industrial nations; piracy as an offshoot. Cardozo J Int Comp Law 10:47Google Scholar
  16. Goodwin PE (2008) Right idea, wrong result – Canada’s access to medicines regime. Am J Law Med 34:567Google Scholar
  17. Harris DP (2006) Carrying a joke too far: TRIPS and treaties of adhesion. Univ Pa J Int Econ Law 27:681Google Scholar
  18. Hestermeyer H (2007) Human rights and the WTO: the case of patents and access to medicines. Oxford University Press, OxfordGoogle Scholar
  19. Hill S, Johnson K (2004) Emerging challenges and opportunities in drug registration and regulation in developing countries. DFID Health System Resource Centre, LondonGoogle Scholar
  20. Ho CM (2011) Access to medicine in the global economy: international agreements on patents and related rights. Oxford University Press, New YorkGoogle Scholar
  21. Kihwelo PF (2006) Intellectual property rights jurisprudence in Tanzania: turning an eye to the commercial division of the High Court. J World Intellect Prop 9:673CrossRefGoogle Scholar
  22. La Croix S, Liu M (2008) Patents and access to essential medicines. In: Maskus KE (ed) Intellectual property, growth and trade. Elsevier, Amsterdam, p 423CrossRefGoogle Scholar
  23. Llewelyn M (2005) Schrodinger’s Cat: an observation on modern patent law. In: Drahos P (ed) Death of patents. Lawtext, London, p 11Google Scholar
  24. Mey BP (2010) Unfettered consumer access to affordable therapies in the post-TRIPS era: a dead-end journey for patients? Kenya and India case studies. J World Intellect Prop 13:403CrossRefGoogle Scholar
  25. Mgbeoji I (2006) Global biopiracy: patents, plants, and indigenous knowledge. UBC Press, VancouverGoogle Scholar
  26. Mgbeoji I (2007) TRIPS and TRIPS-plus impacts in Africa. In: Gervais DJ (ed) Intellectual property, trade and development: strategies to optimize economic development in a TRIPS-Plus era. Oxford University Press, OxfordGoogle Scholar
  27. Mgbeoji I (2011) A promise betrayed? Rethinking the clerical natures of IPRs practice in the Third World. Online: http://www.iposgoode.ca/2011/06/a-promise-betrayed-rethinking-the-clerical-natures-of-iprs-practice-in-the-third-world/
  28. Morin J-F (2006) Tripping up TRIPS debates: IP and health in bilateral agreements. Int J Intellect Prop Manag 1:37CrossRefGoogle Scholar
  29. Musungu SF et al (2004) Utilizing TRIPS flexibilities for public health protection through south-south regional frameworks. South Perspectives Report. Geneva, South CenterGoogle Scholar
  30. Oddi AS (1987) The International Patent System and Third World Development: Reality or Myth? Duke Law J 63:831CrossRefGoogle Scholar
  31. Oguamanam C (2006) International law and indigenous knowledge: intellectual property, plant biodiversity, and traditional medicine. University of Toronto Press, TorontoGoogle Scholar
  32. Oguamanam C (2010) Patents and pharmaceutical R&D: consolidating private–public partnership approach to global public health crises. J World Intellect Prop 13:556Google Scholar
  33. Okediji RL (2004) Africa and the global intellectual property system: beyond the agency model. Afr YB Int Law 12:207Google Scholar
  34. Outterson K (2005) Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J Health Policy Law Ethics 5:193Google Scholar
  35. Outterson K (2008) Should access to medicines and TRIPS flexibilities be limited to specific diseases? Am J Law Med 34:279Google Scholar
  36. Park C (2010) Challenging pharmaceutical patents: the case of India. In: Intellectual property and access to medicines: papers and perspectives. Geneva: WHO, pp 107Google Scholar
  37. Piper ST (2008) The Emergence of a Medical Exception from Patentability in the 20th Century. D. Phil Thesis, University of OxfordGoogle Scholar
  38. Pound R (1960) Mechanical jurisprudence. In: Henson RD (ed) Landmarks of law. Beacon, Boston, p 101Google Scholar
  39. Schovsbo J (2011) Fire and water make steam – redefining the role of competition law in TRIPS. In: Kur A, Levin M (eds) Intellectual property rights in a fair world trade system: proposals for reform of TRIPS. Edward Elgar, Cheltenham, p 308Google Scholar
  40. Seidman A, Seidman RB (1994) State and law in the development process: problem-solving and institutional change in the Third World. Macmillan, BasingstokeGoogle Scholar
  41. Seidman A, Seidman RB (2006) Law in aid of development: ‘Hasty Legal Transplants’ and the fatal race. J Comp Law 1(2):282Google Scholar
  42. Seidman AW, Seidman RB (2008) Lawmaking, development and rule of law. In: Arnscheidt J et al (eds) Lawmaking for development: explorations into the theory and practice of international legislative projects. Leiden University Press, Leiden, p 91Google Scholar
  43. Seidman A et al (2001) Legislative drafting for democratic social change: a manual for drafters. Kluwer Law International, The HagueGoogle Scholar
  44. Sell SK (2003) Private power, public law: the globalization of intellectual property rights. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  45. Smith RD et al (2009) Trade, TRIPS, and pharmaceuticals. Lancet 373:684CrossRefGoogle Scholar
  46. Stiglitz JE (2008) Economic foundations of intellectual property rights. Duke Law J 57:1693Google Scholar
  47. Tabaro E (2009) Patent law reform in Uganda: addressing priorities and strategies. J World Intellect Prop 12:571CrossRefGoogle Scholar
  48. UNAIDS (2011) Using TRIPS flexibilities to improve access to HIV treatment. In: AIDS at 30: nations at the crossroads. Online: http://www.unaids.org/en/resources/unaidspublications/2011/
  49. UNCTAD-ICTSD (2005) Resource book on TRIPS and development. Cambridge University Press, CambridgeCrossRefGoogle Scholar
  50. Vaver D (1997) Intellectual property law copyright, patents, trademarks. Irwin Law, ConcordGoogle Scholar

Treaties and Legislation

  1. Paris Convention for the Protection of Industrial Property, 1883, 21 UST 1538, 828 UNTS 305.Google Scholar
  2. Patent Cooperation Treaty, concluded at Washington on 19 June 1970, amended on 28 September 1979, modified on 3 February 1984, and on 3 October 2001.Google Scholar
  3. Statute of the International Court of Justice, 1976 YBUN 1052.Google Scholar
  4. Harare Protocol on Patents and Industrial Designs, 1982.Google Scholar
  5. Industrial Property Act No. 14 of 1996 (Botswana).Google Scholar
  6. Patents Act, 2003 (Act 657) (Ghana).Google Scholar
  7. Swakopmund Protocol on the Protection of Traditional Knowledge and Expressions of Folklore, 2010(ARIPO).Google Scholar
  8. Drug Price Competition and Patent Term Restoration Act, 1984, Pub L No. 98-417, 98 Stat. 1585 (1984).Google Scholar
  9. High Court (Civil Procedure) Rules, 2004 (CI. 47) (Ghana).Google Scholar
  10. High Court Registries (Amendment) Rules 1999 (Tanzania).Google Scholar
  11. Patent Act No. 57 of 1978 (South Africa).Google Scholar
  12. Patents Act, 2003 (Act 657) (Ghana).Google Scholar
  13. Competition Act No. 89 of 1998 (South Africa).Google Scholar
  14. United Nations Convention on Biological Diversity, 31 ILM 818 (1992).Google Scholar
  15. Swakopmund Protocol on the Protection of Traditional Knowledge and Expressions of Folklore, 2010(ARIPO).Google Scholar
  16. International Covenant on Civil and Political Rights, 16 December 1966, 999 UNTS 171.Google Scholar
  17. Evidence Act, 1975 (NRCD 323) (Ghana).Google Scholar
  18. Limitations Act, 1972 (NRCD 54) (Ghana).Google Scholar
  19. Medicines and Related Substances Control (Amendment) Act No.90 of 1997 (South Africa).Google Scholar

Jurisprudence

  1. Free World Trust v Electro Santé Inc, [2002] 2 SCR 1024, 2000 SCC 66Google Scholar
  2. Novartis AG & Another v Union of India & Others (2007) 4 MLJ 1153.Google Scholar
  3. Hazel Tau and Others v GlaxoSmithKline and Boehringer Ingelheim (South Africa)Google Scholar
  4. Medicross Healthcare Group (Pty) Ltd and Prime Cure Holdings (Pty) Ltd (Competition Tribunal, case no: 11/LM/Mar05, 13 October 2005.Google Scholar
  5. Medicross Healthcare Group (Pty) Ltd and Prime Cure Holdings (Pty) Ltd v The Competition Commission, 55/CAC/Sep05.Google Scholar
  6. Doctors for Life International v The Speaker of the National Assembly & Others, 2006 (12) BCLR 1399 (CC) (SA).Google Scholar

Documents

  1. World Bank, World Development Indicators, 2000.Google Scholar
  2. Extension of the Transition Period under Article 66.1 for Least-Developed Country Members (29 November 2005).Google Scholar
  3. World Bank, World Development Indicators, 2000.Google Scholar
  4. National Drug Policy for South Africa (1996) (South Africa).Google Scholar
  5. UNAIDS. AIDS at 30: Nations at the Crossroads (2011).Google Scholar
  6. Mgbeoji, Ikechi. “A Promise Betrayed? Rethinking the Clerical Natures of IPRs Practice in the Third World”, online: <http://www.iposgoode.ca/2011/06/a-promise-betrayed-rethinking-the-clerical-natures-of-iprs-practice-in-the-third-world/>.

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Faculty of LawUniversity of GhanaAccraGhana

Personalised recommendations